Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Betulinic Acid for Dysplastic Nevi
NCT00346502Phase 2Withdrawn
- Sponsor
- University of Illinois Chicago
- Start
- Jan 2006
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of betulinic acid in dysplastic nevus syndrome (DNS), sponsored by University of Illinois Chicago. Planned start Jan 2006; status: withdrawn.
02
Drugs
betulinic acid
03
Conditions
dysplastic nevus syndrome (DNS)
Beyond the preview
Go deeper on NCT00346502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00346502.